The impact of the acquired immunodeficiency syndrome (AIDS) pandemic on the treatment of patients with end-stage renal disease (ESRD) is felt throughout the world, but nowhere more palpably than in the United States. Through June 30, 1997, a cumulative total of 612,078 persons with AIDS were reported to the Centers for Disease Control (CDC). Currently, nearly 240,000 people are living with AIDS in the United States, with an annual incidence of 50,000-60,000 new cases per year. It is estimated that over one million persons are infected with the human immunodeficiency virus (HIV). Worldwide, by the beginning of 1997 a cumulative total of 29.4 million people had been infected with HIV and a cumulative 8.4 million cases of AIDS had been documented (1,2). For the first time, however, the number of deaths among patients with AIDS declined in the United States from 50,700 in 1995 to 39,200 in 1996. As improvements in antiretroviral therapy and prophylaxis of opportunistic infections continue, more patients with AIDS will live longer and may be at risk for developing ESRD (3-5).
|Original language||English (US)|
|Title of host publication||Complications of Dialysis|
|Number of pages||15|
|State||Published - Jan 1 2000|
ASJC Scopus subject areas